Literature DB >> 33723056

Decoupling expression and editing preferences of ADAR1 p150 and p110 isoforms.

Tony Sun1, Yingpu Yu1, Xianfang Wu1, Ashley Acevedo1, Ji-Dung Luo2, Jiayi Wang1, William M Schneider1, Brian Hurwitz3, Brad R Rosenberg4, Hachung Chung5, Charles M Rice6.   

Abstract

Human adenosine deaminase acting on RNA 1 (ADAR1) catalyzes adenosine-to-inosine deamination reactions on double-stranded RNA molecules to regulate cellular responses to endogenous and exogenous RNA. Defective ADAR1 editing leads to disorders such as Aicardi-Goutières syndrome, an autoinflammatory disease that manifests in the brain and skin, and dyschromatosis symmetrica hereditaria, a skin pigmentation disorder. Two ADAR1 protein isoforms, p150 (150 kDa) and p110 (110 kDa), are expressed and can edit RNA, but the contribution of each isoform to the editing landscape remains unclear, largely because of the challenges in expressing p150 without p110. In this study, we demonstrate that p110 is coexpressed with p150 from the canonical p150-encoding mRNA due to leaky ribosome scanning downstream of the p150 start codon. The presence of a strong Kozak consensus context surrounding the p110 start codon suggests the p150 mRNA is optimized to leak p110 alongside expression of p150. To reduce leaky scanning and translation initiation at the p110 start codon, we introduced synonymous mutations in the coding region between the p150 and p110 start codons. Cells expressing p150 constructs with these mutations produced significantly reduced levels of p110. Editing analysis of total RNA from ADAR1 knockout cells reconstituted separately with modified p150 and p110 revealed that more than half of the A-to-I edit sites are selectively edited by p150, and the other half are edited by either p150 or p110. This method of isoform-selective editing analysis, making use of the modified p150, has the potential to be adapted for other cellular contexts.

Entities:  

Keywords:  ADAR1; RNA editing; p110; p150

Mesh:

Substances:

Year:  2021        PMID: 33723056      PMCID: PMC8000508          DOI: 10.1073/pnas.2021757118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   12.779


  41 in total

1.  uORFs, reinitiation and alternative translation start sites in human mRNAs.

Authors:  Alex V Kochetov; Shandar Ahmad; Vladimir Ivanisenko; Oxana A Volkova; Nikolay A Kolchanov; Akinori Sarai
Journal:  FEBS Lett       Date:  2008-03-20       Impact factor: 4.124

2.  Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR.

Authors:  Alan Herbert
Journal:  Eur J Hum Genet       Date:  2019-07-18       Impact factor: 4.246

3.  A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs.

Authors:  R W Wagner; J E Smith; B S Cooperman; K Nishikura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Characterization of the 5'-flanking region of the human RNA-specific adenosine deaminase ADAR1 gene and identification of an interferon-inducible ADAR1 promoter.

Authors:  C X George; C E Samuel
Journal:  Gene       Date:  1999-03-18       Impact factor: 3.688

5.  A Z-DNA binding domain present in the human editing enzyme, double-stranded RNA adenosine deaminase.

Authors:  A Herbert; J Alfken; Y G Kim; I S Mian; K Nishikura; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  CRM1 mediates the export of ADAR1 through a nuclear export signal within the Z-DNA binding domain.

Authors:  H Poulsen; J Nilsson; C K Damgaard; J Egebjerg; J Kjems
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

7.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature.

Authors:  Gillian I Rice; Paul R Kasher; Gabriella M A Forte; Niamh M Mannion; Sam M Greenwood; Marcin Szynkiewicz; Jonathan E Dickerson; Sanjeev S Bhaskar; Massimiliano Zampini; Tracy A Briggs; Emma M Jenkinson; Carlos A Bacino; Roberta Battini; Enrico Bertini; Paul A Brogan; Louise A Brueton; Marialuisa Carpanelli; Corinne De Laet; Pascale de Lonlay; Mireia del Toro; Isabelle Desguerre; Elisa Fazzi; Angels Garcia-Cazorla; Arvid Heiberg; Masakazu Kawaguchi; Ram Kumar; Jean-Pierre S-M Lin; Charles M Lourenco; Alison M Male; Wilson Marques; Cyril Mignot; Ivana Olivieri; Simona Orcesi; Prab Prabhakar; Magnhild Rasmussen; Robert A Robinson; Flore Rozenberg; Johanna L Schmidt; Katharina Steindl; Tiong Y Tan; William G van der Merwe; Adeline Vanderver; Grace Vassallo; Emma L Wakeling; Evangeline Wassmer; Elizabeth Whittaker; John H Livingston; Pierre Lebon; Tamio Suzuki; Paul J McLaughlin; Liam P Keegan; Mary A O'Connell; Simon C Lovell; Yanick J Crow
Journal:  Nat Genet       Date:  2012-09-23       Impact factor: 38.330

8.  RNA binding-independent dimerization of adenosine deaminases acting on RNA and dominant negative effects of nonfunctional subunits on dimer functions.

Authors:  Louis Valente; Kazuko Nishikura
Journal:  J Biol Chem       Date:  2007-04-11       Impact factor: 5.157

9.  Extensive editing of cellular and viral double-stranded RNA structures accounts for innate immunity suppression and the proviral activity of ADAR1p150.

Authors:  Christian K Pfaller; Ryan C Donohue; Stepan Nersisyan; Leonid Brodsky; Roberto Cattaneo
Journal:  PLoS Biol       Date:  2018-11-29       Impact factor: 8.029

Review 10.  ADAR1 Editing and its Role in Cancer.

Authors:  Li-Di Xu; Marie Öhman
Journal:  Genes (Basel)       Date:  2018-12-25       Impact factor: 4.096

View more
  7 in total

1.  The E3 ubiquitin ligase SMURF2 stabilizes RNA editase ADAR1p110 and promotes its adenosine-to-inosine (A-to-I) editing function.

Authors:  Praveen Koganti; Venkata Narasimha Kadali; Dhanoop Manikoth Ayyathan; Andrea Emanuelli; Biagio Paolini; Gal Levy-Cohen; Michael Blank
Journal:  Cell Mol Life Sci       Date:  2022-04-11       Impact factor: 9.261

Review 2.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

Review 3.  ADAR1-Mediated RNA Editing and Its Role in Cancer.

Authors:  Jizhe Liu; Fei Wang; Yindan Zhang; Jingfeng Liu; Bixing Zhao
Journal:  Front Cell Dev Biol       Date:  2022-07-11

4.  Adar-mediated A-to-I editing is required for embryonic patterning and innate immune response regulation in zebrafish.

Authors:  Katarzyna Niescierowicz; Leszek Pryszcz; Cristina Navarrete; Eugeniusz Tralle; Agata Sulej; Karim Abu Nahia; Marta Elżbieta Kasprzyk; Katarzyna Misztal; Abhishek Pateria; Adrianna Pakuła; Matthias Bochtler; Cecilia Winata
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694

5.  Survey of the binding preferences of RNA-binding proteins to RNA editing events.

Authors:  Xiaolin Hu; Qin Zou; Li Yao; Xuerui Yang
Journal:  Genome Biol       Date:  2022-08-04       Impact factor: 17.906

6.  Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes.

Authors:  Samantha Bannister; Bowon Kim; Jorge Domínguez-Andrés; Gizem Kilic; Brendan R E Ansell; Melanie R Neeland; Simone J C F M Moorlag; Vasiliki Matzaraki; Amanda Vlahos; Rebecca Shepherd; Susie Germano; Melanie Bahlo; Nicole L Messina; Richard Saffery; Mihai G Netea; Nigel Curtis; Boris Novakovic
Journal:  Sci Adv       Date:  2022-08-05       Impact factor: 14.957

Review 7.  An I for an A: Dynamic Regulation of Adenosine Deamination-Mediated RNA Editing.

Authors:  Cornelia Vesely; Michael F Jantsch
Journal:  Genes (Basel)       Date:  2021-07-01       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.